<DOC>
	<DOC>NCT00841945</DOC>
	<brief_summary>Prospective and multicentric Phase III study, evaluation of the interest of the radiotherapy after 4 or 6 cycles of CHOP 14 R regimen of chemotherapy , patients with agressive and localized B lymphoma , age 18 to 75 years.</brief_summary>
	<brief_title>Treatment of Aggressive Localized Lymphoma</brief_title>
	<detailed_description>CHOP 14 R regimen of chemotherapy is a good standard in the treatment of agressive and localized B lymphoma. Interest of the radiotheraphy</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Age &gt; 18 and &lt; 75 years Diffuse B large cell lymphoma , CD 20+ Ann Arbor stage I or II withe a bulk &lt;7 cm stage i ou II confirmed by the PETscan No previously treated HIV negative Signed Informed consent Age&lt; 18 and &gt; 75 years other type of lymphoma CD20 negative Ann Arbor stage &gt;II or bulk &gt; 7 cm HIV positive Contraindication to Rituximab use according to Sm PC Containdication to antracyclin cancer or history of cancer , excepted in situ cancer of the cervix or skin epithelioma Refusal of sign the informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diffuse B larg cell lymphoma</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>